ACADIA Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Good morning. So welcome to day 2 of the 2020 Cantor Global Healthcare Conference. My name is Charles Duncan. I'm a senior biotechnology analyst and managing director for Cantor. And I'm excited to introduce the next presenting company, which is ACADIA Pharmaceuticals. The ticker symbol on ACADIA is ACAD. We rate it with an overweight rating and $61 price target, and it's a company that I've known for many years.
I would consider one of the original neuro innovator companies, company that has not only developed a drug successfully, but forward integrated to become a fully commercial organization.
It's been a very interesting year for you. And so I'm excited to introduce senior management Mr. Steve Davis, the company's CEO; and Michael Yang, the company's Chief Commercial Officer; as well as Mark Johnson, who's on the line from IR. Gentlemen, thank you for joining us.
Thank you.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
